A Multimodal Model Based on Transvaginal Ultrasound-Based Radiomics to Predict the Risk of Peritoneal Metastasis in Ovarian Cancer: A Multicenter Study.
Authors
Affiliations (3)
Affiliations (3)
- Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China (Y.Z., Y.D., Q.Z., C.Z.).
- Department of Ultrasound, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui, China (S.L.).
- Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China (Y.Z., Y.D., Q.Z., C.Z.). Electronic address: [email protected].
Abstract
This study aimed to develop a predictive model for peritoneal metastasis (PM) in ovarian cancer using a combination radiomics and clinical biomarkers to improve diagnostic accuracy. This retrospective cohort study of 619 ovarian cancer patients involved demographic data, radiomics, O-RADS standardized description, clinical biomarkers, and histological findings. Radiomics features were extracted using 3D Slicer and Pyradiomics, with selective feature extraction using Least Absolute Shrinkage and Selection Operator regression. Model development and validation were carried out using logistic regression and machine learning methods RESULTS: Interobserver agreement was high for radiomics features, with 1049 features initially extracted and 7 features selected through regression analysis. Multi-modal information such as Ascites, Fallopian tube invasion, Greatest diameter, HE4 and D-dimer levels were significant predictors of PM. The developed radiomics nomogram demonstrated strong discriminatory power, with AUC values of 0.912, 0.883, and 0.831 in the training, internal test, and external test sets respectively. The nomogram displayed superior diagnostic performance compared to single-modality models. The integration of multimodal information in a predictive model for PM in ovarian cancer shows promise for enhancing diagnostic accuracy and guiding personalized treatment. This multi-modal approach offers a potential strategy for improving patient outcomes in ovarian cancer management with PM.